The Lead Episode 147: Heart Rhythm 2026 Late Breaker Coverage: A Discussion of Proton Beam Cardiac Radioablation for Refractory Ventricular Tachycardia: Results from a Frist-in-Human, Prospective, Non-Randomized Trial-The Lead Episode 147 Bonus Video

Video Transcription

Video Summary

A late-breaking Heart Rhythm trial evaluated catheter-free ventricular tachycardia ablation using proton beam therapy, aiming to improve the safety of cardiac radioablation by exploiting the Bragg peak to reduce radiation to surrounding tissue. In this prospective, nonrandomized feasibility study, seven very sick patients with refractory ventricular arrhythmias, low LVEF, ICDs, and prior failed ablations received targeted proton treatment. The team achieved concentrated dosing with limited exposure to non-target myocardium and no device malfunctions or major treatment-related adverse events. Over about 514 days of follow-up, VT/BT episodes decreased from 7.3 to 1.5 per patient-month, though recurrence remained common. Experts praised the technical achievement but stressed major limitations: tiny sample size, short follow-up for radiation effects, high cost, limited availability of proton centers, and the need for larger comparative trials versus photon therapy before it could become standard.

Keywords

proton beam therapy

ventricular tachycardia ablation

cardiac radioablation

Bragg peak

refractory ventricular arrhythmias